March 23, 2022 -- Seqens has made a multimillion-dollar investment into its research and development laboratory based in Devens, MA. The project is expected to be completed in October 2022, the company said.
The investment will go toward improvements in the facility's safety and quality capacities, and it will be used to strengthen its R&D capabilities and productivity, Seqens said.
The investment will also enhance the company's involvement and commitment to U.S. operations, adding to Seqens' existing sales offices and a contract development and manufacturing operation already located in Newburyport, MA.
Furthermore, this investment follows SK Capital becoming a majority holder in Seqens through a merger with its portfolio company Wavelength Pharmaceuticals.
Wavelength's additional capabilities will enable the company to have greater reach and a more diverse portfolio of active pharmaceutical ingredients, as well as cytotoxic, steroidal, and high-potency products, Seqens said.
Copyright © 2022 scienceboard.net